Immune thrombocytopenia successfully treated with eltrombopag following multiple therapies including romiplostim

被引：6
|
作者：
Sartori, Roberto [1 ,2 ]
Candiotto, Laura [1 ,2 ]
Ruggeri, Marco [3 ]
Tagariello, Giuseppe [1 ,2 ]
机构：
[1] Castelfranco Veneto Hosp, Haemophilia Ctr, Transfus Serv, I-31033 Castelfranco Veneto, TV, Italy
[2] Castelfranco Veneto Hosp, Dept Haematol, I-31033 Castelfranco Veneto, TV, Italy
[3] San Bortolo Hosp, Dept Cell Therapy & Haematol, Vicenza, Italy
来源：
BLOOD TRANSFUSION | 2014年 / 12卷
关键词：
D O I：
10.2450/2013.0135-13
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：S151 / S152
页数：2
相关论文
共 50 条
  • [21] Predictors of Remission in Adults with Immune Thrombocytopenia Treated with Romiplostim
    Newland, Adrian
    Bussel, James B.
    Bird, Robert
    Arnold, Donald M.
    Kessler, Craig M.
    Mayer, Jiri
    Romero, Monica Tejeda
    Janssens, Ann
    Wang, Kejia
    Eisen, Melissa Jeanne
    BLOOD, 2018, 132
  • [22] Cost-Consequence Model Comparing Eltrombopag and Romiplostim for Pediatric Patients with Previously-Treated Chronic Immune Thrombocytopenia
    Tremblay, Gabriel
    Bhor, Menaka
    Roy, Anuja
    Elliott, Brian
    Dolph, Mike
    Forsythe, Anna
    Briggs, Andrew
    BLOOD, 2017, 130
  • [23] Durability of platelet response after switching to avatrombopag from eltrombopag or romiplostim in immune thrombocytopenia
    Al-Samkari, Hanny
    Jiang, Debbie
    Gernsheimer, Terry
    Liebman, Howard
    Lee, Susie
    Bernheisel, Chelsea
    Wojdyla, Matthew
    Vredenburg, Michael
    Cuker, Adam
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2023, 7 (03)
  • [24] Diagnosis of venous thromboembolism during eltrombopag therapy for immune thrombocytopenia and successful replacement with romiplostim
    Amit, O.
    Kirgner, I
    Avivi, I
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 606 - 607
  • [25] Transcriptomic analysis of patients with immune thrombocytopenia treated with eltrombopag
    Maria Hernandez-Sanchez, Jesus
    Maria Bastida, Jose
    Alonso-Lopez, Diego
    Benito, Rocio
    Ramon Gonzalez-Porras, Jose
    De Las Rivas, Javier
    Hernandez Rivas, Jesus Maria
    Eugenia Rodriguez-Vicente, Ana
    PLATELETS, 2020, 31 (08) : 993 - 1000
  • [26] A CASE OF REFRACTORY IMMUNE THROMBOCYTOPENIA (ITP) SUCCESSFULLY TREATED WITH ROMIPLOSTIM IN A PATIENT AFFECTED BY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Guidotti, F.
    Maura, F.
    Reda, G.
    Gregorini, A.
    Cortelezzi, A.
    HAEMATOLOGICA, 2012, 97 : 528 - 528
  • [27] Switching From Romiplostim to Eltrombopag or Vice Versa for Immune Thrombocytopenia: Efficacy and Safety in 46 Patients
    Khellaf, Mehdi
    Viallard, Jean-Francois
    Hamidou, Mohamed
    Cheze, Stephane
    Lefrere, Francois
    Fain, Olivier
    Audia, Sylvain
    Jardin, Fabrice
    Gyan, Emmanuel
    Durand, Jean Marc
    Haioun, Corinne
    Bierling, Philippe
    Michel, Marc
    Godeau, Bertrand
    BLOOD, 2012, 120 (21)
  • [28] Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia
    Al-Samkari, Hanny
    Kuter, David J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 183 (02) : 168 - 168
  • [29] Cost-Effectiveness of Eltrombopag versus Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in England and Wales
    Allen, Rachel
    Bryden, Peter
    Grotzinger, Kelly M.
    Stapelkamp, Ceilidh
    Woods, Bethan
    VALUE IN HEALTH, 2016, 19 (05) : 614 - 622
  • [30] Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia
    Tremblay, Gabriel
    Dolph, Mike
    Bhor, Menaka
    Said, Qayyim
    Roy, Anuja
    Elliott, Brian
    Briggs, Andrew
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2018, 10 : 715 - 721
12345